Loading data for PRQR — first visit, this takes a few seconds.
ProQR Therapeutics N.V. (PRQR)
NasdaqCM: PRQR
· 即時價格 · USD
1.88
-0.06 (-3.09%)
收盤價： Sep 11, 2026, 8:00 PM
1.93
+3.76%
盤後: 7:58 PM
股價、關鍵數字和最新消息，都在這一頁。
ProQR Therapeutics N.V.（PRQR）股價、分析與資料
無可用資料
| 買價 | 1.4 |
| 市值 | 262M |
| 營收 (ttm) | 18.4M |
| 淨利（ttm） | -42M |
| 0.06 | |
| -0.45 | |
| n/a | |
| -3.93 | |
| P/B (ttm) | 2.21 |
| P/S (ttm) | 14.25 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 2.39 |
| 成交量 | 356,049 |
| 20 日平均成交量 | 1,117,900 |
| 開盤價 | 1.97 |
| 前收盤價 | 1.94 |
| 當日區間 | 1.87 - 1.98 |
| 52 週範圍 | 1.33 - 3.10 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 PRQR
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targe...
完整的公司簡介財報驚奇
ProQR Therapeutics 已於 Aug 13, 2026 公布季度財報：
- 營收為 $8.76M 低於預期 $0, 年增 129.47% 成長.
- 每股盈餘為 -0.09 超出預期 0.09, 年增 35.71% 成長.
第 1 頁，共 2 頁